Fungal infections in nontransplant patients with hematologic malignancies (Q35038473)

5 August 2017

1 reference

title

Fungal infections in nontransplant patients with hematologic malignancies (English)

1 reference

5 August 2017

Brahm H Segal

1

1 reference

5 August 2017

Eric J Bow

series ordinal

2

1 reference

5 August 2017

Francisco Menichetti

series ordinal

3

1 reference

5 August 2017

language of work or name

1 reference

1 December 2002

1 reference

Infectious Disease Clinics of North America

5 August 2017

1 reference

5 August 2017

16

1 reference

5 August 2017

935-64, vii

1 reference

5 August 2017

4

1 reference

Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and preserved Fcgamma receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Infections of hairy cell leukemia. Clinical evidence of a pronounced defect in cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Clinical presentation of infection in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Invasive aspergillosis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Revisiting the Source of Candidemia: Skin or Gut?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Infectious complications of immunosuppressive therapy in patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Glucocorticosteroid therapy: mechanisms of action and clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Incidence of infection in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathog

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Infections in patients with chronic lymphocytic leukemia treated with fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Nosocomial fungaemia: a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Risk Factors for Candida tropicalis fungemia in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Candida tropicalis: A Major Pathogen in Immunocompromised Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Should vascular catheters be removed from all patients with candidemia? An evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Hepatic candidiasis in cancer patients: the evolving picture of the syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Aspergillus sinusitis in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Pneumocystis carinii pneumonia in patients without AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Pneumocystis carinii pneumonia in patients with primary brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

CT and MRI manifestations of central nervous system infection following allogeneic bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Therapeutic outcome in invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Prognostic factors in cryptococcal meningitis. A study in 111 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Catastrophic visual loss due to Cryptococcus neoformans meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Adjunctive immune therapy for fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Early Clinical Recognition of Disseminated Candidiasis by Muscle and Skin Biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Trichosporonosis in patients with neoplastic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Invasive Aspergillus infections in a pediatric hospital: a ten-year review.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Primary cutaneous aspergillosis--an emerging infection among immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Aspergillosis. The spectrum of the disease in 98 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Fungal infections complicating acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Effects of granulocyte colony-stimulating factor and interferon-gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Use of macrophage colony-stimulating factor in the treatment of fungal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Granulocyte transfusions. Time for a second look

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Evaluation and comparison of three mobilization methods for the collection of granulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Interferon-gamma in the management of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Combination immunotherapy and antifungal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

T cell vaccination in mice with invasive pulmonary aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

Immunomodulation for the treatment of invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

NIH conference. Respiratory disease in the immunosuppressed patient

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900043-0

7 January 2021

10.1016/S0891-5520(02)00043-0

Identifiers

DOI

1 reference

release_7rh4kium4rh57bo5ifw66cmchy

5 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7rh4kium4rh57bo5ifw66cmchy

24 November 2022

mapped directly with Wikidata item

1 reference